Stephanie Dorman received funding under a grant from the Breast Cancer Society of Canada to perform some incredible research at the Translational Breast Cancer Research Unit (TBCRU) at London Health Sciences Centre. TBCRU trainee Stephanie Dorman (far right) is a PhD candidate in the Department of Biochemistry from the University of Western Ontario in Professor Peter Rogan’s laboratory. She is analyzing the genomes of breast cancer samples from The Cancer Genome Atlas to better understand which genes are essential for tumor survival. Her goal is to better predict chemotherapy response for drugs that target the products of these genes. She was an author on a related study presented at the 2013 European Society of Human Genetics annual meeting in Paris (pictured at right, with Professor Rogan and co‐author Dr. Joan Knoll), and presented her progress at the Istituto Nazionale dei Tumori in Milan.
With support from the TBCRU, Stephanie recently published a method that improves the accuracy of a test commonly used in the genetic analysis of many types of cancers (Dorman et. al. Expanding probe repertoire and improving reproducibility in human genomic hybridization, Nucleic Acids Research, 41:e81, 2013).
The Breast Cancer Society of Canada works very closely with the Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit (TBCRU) under the direction of Dr. Ann Chambers. Each year, the Society grants the TCBRU unit with $500,000.00. These funds further the world-renowned work of the unit specializing in “personalized” treatment for breast cancer patients. The grant is used to support many aspects of the unit including funding for Studentships, Post-Doctoral Fellowships, and seed funding for new ideas.